Results 11 to 20 of about 1,793 (169)

Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient [PDF]

JAAD Case Reports, 2020
Matthew D Vesely
exaly   +2 more sources

Alopecia totalis successfully treated with modified platelet-rich plasma therapy in a patient recalcitrant to traditional treatment modalities

Clinical Dermatology Review, 2021
Alopecia areata (AA) is an autoimmune, nonscarring, inflammatory disorder of the scalp and/or body resulting in hair loss. Extensive AA such as alopecia totalis is increasingly unresponsive to conventional treatment modalities.
Sumit Gupta, Priyanka Borde Bisht, Charisma Kannan   +2 more
doaj   +1 more source

Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis

Acta Dermato-Venereologica, 2023
Alopecia areata is an autoimmune disorder characterized by hair loss, for which there are few treatment options. This claims-based study characterized recent real-world treatment patterns among patients in the USA with alopecia areata, including the ...
Nicolae Done, Lauren Bartolome, Elyse Swallow, Wei Gao, Christopher Carley, Travis Wang, Arash Mostaghimi   +6 more
doaj   +1 more source

Improvement of atopic dermatitis and alopecia universalis with dupilumab: a case report

Dermatology Reports, 2021
Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that showed significant improvement of atopic dermatitis (AD). Many reports have shown significant resolution of alopecia areata, alopecia universalis, and alopecia totalis after dupilumab ...
Lama Alotaibi, Abdulrahman Alfawzan, Raghad Alharthi, Afaf Al sheikh   +3 more
doaj   +1 more source

Hydroxychloroquine for granuloma annulare: A case report on secondary hair growth in alopecia universalis

SAGE Open Medical Case Reports, 2023
Alopecia areata is an autoimmune disease resulting in non-scarring hair loss. Alopecia areata can progress to become alopecia totalis (loss of hair from the entire scalp) or alopecia universalis (loss of hair form the entire body), with the progression ...
Selena Osman, Danya Traboulsi
doaj   +1 more source

Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis. [PDF]

Cureus
Objectives Tofacitinib, an effective Janus kinase inhibitor (JAKi), has gained increasing interest in recent years for the management of refractory alopecia areata (AA). One of the most prevalent autoimmune diseases is AA, a kind of non-scarring alopecia.
Tirmizi SS, Ahmed MK, Iqbal T, Hashmi AA.   +3 more
europepmc   +3 more sources

A Case of Azathioprine Induced Severe Myelosuppression and Alopecia Totalis in IgA Nephropathy [PDF]

Childhood Kidney Diseases, 2017
Azathioprine is commonly used as immunosuppressive therapy for various inflammatory diseases including chronic glomerulonephritis. Myelosuppression is a common side effect of azathioprine, resulting in the need for dose reduction.
Jae Choon Kim, Ye Kyung Kim, Hye Sun Hyun, Eu Jin Park, Hee Gyung Kang, Il Soo Ha, Hae Il Cheong   +6 more
doaj   +1 more source

Progress in immune pathogenesis and targeted therapy of alopecia areata

Pifu-xingbing zhenliaoxue zazhi, 2023
Alopecia areata is a common clinical non-cicatricial alopecia. Alopecia totalis and generalized alopecia may occur in severe cases. The pathogenesis of alopecia areata is complex, and the treatment is faced with many difficulties.
Jiali WANG, Dantong CHENG, Nana LUO, Pingsheng HAO   +3 more
doaj   +1 more source

Scalp micro-needling: A new tool in the treatment of alopecia totalis

Clinical Dermatology Review, 2020
Alopecia areata is the most common form of nonscarring alopecia. It may vary from a single round patch to that involving large surface area termed as alopecia totalis (AT).
Savitha L Beergouder, Apoorva Reshme
doaj   +1 more source

The Role of Tofacitinib in the Management of Alopecia Totalis. [PDF]

Sultan Qaboos Univ Med J, 2019
Medical ...
Hernandez-Montoya C, Ruiz-Villaverde R.
europepmc   +5 more sources